Mice with disseminated candidiasis die of progressive sepsis

Journal of Infectious Diseases

Volumn 192, Issue 2, 2005, Pages 336-343

  Spellberg, Brad ^a,b,c   Ibrahim, Ashraf S ^a,b   Edwards Jr , John E ^a,b   Filler, Scott G ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ACIDEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CANDIDA; CANDIDIASIS; CAUSE OF DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; HEMODYNAMICS; HOSPITAL INFECTION; HYPOGLYCEMIA; HYPOTENSION; HYPOTHERMIA; KIDNEY FAILURE; MALE; METABOLIC ACIDOSIS; MORTALITY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS; TACHYCARDIA; TECHNOLOGY; WEIGHT REDUCTION;

ANIMALS; BLOOD CHEMICAL ANALYSIS; BLOOD PRESSURE; BODY TEMPERATURE; BODY WEIGHT; CANDIDIASIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEMODYNAMIC PROCESSES; HYPOTENSION; HYPOTHERMIA; MALE; MICE; MICE, INBRED BALB C; SEPSIS; SURVIVAL ANALYSIS; TACHYCARDIA;

EID: 22244484044     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/430952     Document Type: Article

References (44)

1. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29:253-8.
2. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91:72S-5S.
3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239-44.
4. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-7.
5. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634-43.
6. Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003; 22:254-7.
7. Valentin A, Le Guennec R, Rodriguez E, Reynes J, Mallie M, Bastide JM. Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model. Antimicrob Agents Chemother 1996; 40:1342-5.
8. 5,6-desaturation. FEBS Lett 1997; 400: 80-2.
9. Collin B, Clancy CJ, Nguyen MH. Antifungal resistance in non-albicans Candida species. Drug Resist Updat 1999; 2:9-14.
10. Muller FM, Weig M, Peter J, Walsh TJ. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 2000; 46:338-40.
11. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181:309-16.
12. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous C. albicans mutants are avirulent. Cell 1997; 90: 939-49.
13. Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, Kullberg BJ. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002; 185:1483-9.
14. Netea MG, Blok WL, Kullberg BJ, et al. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995; 171:393-9.
15. Netea MG, van Tits LJ, Curfs JH, et al. Increased susceptibility of TNF-α lymphotoxin-α double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans. J Immunol 1999; 163:1498-505.
16. Kullberg BJ, Netea MG, Vonk AG, van der Meer JW. Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice. FEMS Immunol Med Microbiol 1999; 26:299-307.
17. Vonk AG, Netea MG, Van Krieken JH, Van Der Meer JW, Kullberg BJ. Delayed clearance of intraabdominal abscesses caused by Candida albicans in tumor necrosis factor-α- and lymphotoxin-α-deficient mice. J Infect Dis 2002; 186:1815-22.
18. -/-) mice. J Infect Dis 1998; 178:478-87.
19. -/- BALB/cmice. J Leukoc Biol 1999; 66:144-50.
20. + lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun 1989; 57:3581-7.
21. Davis D, Edwards JE Jr, Mitchell AP, Ibrahim AS. Candida albicans RIM101 pH response pathway is required for host-pathogen interactions. Infect Immun 2000; 68:5953-9.
22. Ghannoum MA, Spellberg B, Saporito-Irwin SM, Fonzi WA. Reduced virulence of Candida albicans PHR1 mutants. Infect Immun 1995; 63: 4528-30.
23. Brieland J, Essig D, Jackson C, et al. Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect Immun 2001; 69: 5046-55.
24. Clemons KV, Stevens DA. Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis. J Antimicrob Chemother 2001; 47:183-6.
25. Hanson LH, Perlman AM, Clemons KV, Stevens DA. Synergy between cilofungin and amphotericin B in a murine model of candidiasis. Antimicrob Agents Chemother 1991; 35:1334-7.
26. Graybill JR, Bocanegra R, Najvar LK, Hernandez S, Larsen RA. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother 2003; 47:2373-5.
27. Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 2000; 44:1463-9.
28. Jensen J, Warner T, Balish E. Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: role of polymorphonuclear leukocytes and macrophages. J Infect Dis 1993; 167: 912-9.
29. Louria DB, Fallon N, Browne HG. The influence of cortisone on experimental fungus infections in mice. J Clin Invest 1960; 39:1435-49.
30. Meister H, Heymer B, Schafer H, Haferkamp O. Role of Candida albicans in granulomatous tissue reactions. II. In vivo degradation of C. albicans in hepatic macrophages of mice. J Infect Dis 1977; 135:235-42.
31. Morelli R, Rosenberg LT. The role of complement in the phagocytosis of Candida albicans by mouse peripheral blood leukocytes. J Immunol 1971; 107:476-80.
32. Pearsall NN, Adams BL, Bunni R. Immunologic responses to Candida albicans. III. Effects of passive transfer of lymphoid cells or serum on murine candidiasis. J Immunol 1978; 120:1176-80.
33. Tabeta H, Mikami Y, Abe F, Ommura Y, Arai T. Studies on defense mechanisms against Candida albicans infection in congenitally athymic nude (nu/nu) mice. Mycopathologia 1984; 84:107-13.
34. Louria DB. Candida infections in experimental animals. In: Bodey GP, Fainstein V, eds. Candidiasis. New York: Raven Press, 1985:29-51.
35. Leunk RD, Moon RJ. Physiological and metabolic alterations accompanying systemic candidiasis in mice. Infect Immun 1979; 26:1035-41.
36. Spellberg BJ, Johnston D, Phan QT, et al. Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun 2003; 71:5756-64.
37. Tsuchimori N, Sharkey LL, Fonzi WA, French SW, Edwards JE Jr, Filler SG. Reduced virulence of HWP1-deficient mutants of Candida albicans and their interactions with host cells. Infect Immun 2000; 68:1997-2002.
38. Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Fauci AS, Braundwald E, Isselbacher KJ, et al., eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998:269-71.
39. Marino PL. The ICU Book. 2nd ed. Baltimore: Williams & Wilkins, 1998.
40. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
41. Spellberg BJ, Edwards JE Jr. The pathophysiology and treatment of Candida sepsis. Curr Infect Dis Rep 2002; 4:387-99.
42. Nikonenko BV, Samala R, Einck L, Nacy CA. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48:4550-5.
43. Daniel N, Lounis N, Ji B, et al. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice: long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit Care Med 2000; 161:1572-7.
44. Nikonenko BV, Averbakh MM Jr, Lavebratt C, Schurr E, Apt AS. Comparative analysis of mycobacterial infections in susceptible I/St and resistant A/Sn inbred mice. Tuber Lung Dis 2000; 80:15-25.